Cases & Deals

  • Home
  • Practices
  • Celgene successfully blocks PTAB institution of IPR involving REVLIMID®

Share

Celgene successfully blocks PTAB institution of IPR involving REVLIMID®

March 2019

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of a patent covering the use of Celgene's REVLIMID® brand drug to treat multiple myeloma. Alvogen Pine Book LLC ("Alvogen") filed a petition seeking review of U.S. Patent No. 7,968,569, which is directed to methods of treating multiple myeloma with REVLIMID®. Following Celgene's filing of its Patent Owner Preliminary Response to Alvogen's petition, the Patent Trial and Appeal Board ("PTAB") denied institution of inter partes review on March 14, 2019, finding that Alvogen had not shown a reasonable likelihood of prevailing in its unpatentability challenges because it failed to establish that the claimed methods would have been obvious at the time of the invention.

Alvogen Pine Brook, LLC, et al. v. Celgene Corporation, IPR No. 2018-01714 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.